SPY382.33-9.44 -2.41%
DIA313.98-5.55 -1.74%
IXIC13,119.43-478.54 -3.52%

Insider Trends: ChemoCentryx Insider Disposition Interrupting 90-Day Buy Trend

· 02/04/2021 15:15

08:00 PM EST, 02/04/2021 (MT Newswires) -- On Feb 02, 2021, Director, Thomas A Edwards, executed a sale of 20,000 shares in ChemoCentryx (CCXI) for $1,218,844. Edwards, subsequent to the transactions designated in the SEC Form 4 filing, has 121,357 company shares, with a market value, based on the prior-day closing price, of $7.63 million.

Over the last 90 days, prior to the date of this filing, there have been 15 insider transactions reported to the SEC for ChemoCentryx. These transactions came from the activities of 5 separate insiders that resulted in a net acquisition of 38,737 company shares. This compares with the preceding 90-day window of time where there are no insider transactions for the company.

This is a lower level of transactions than the peer group average in the 55-company Biopharmaceuticals peer group over the last 90-day period. Within the peer group activity averaged 47.0 transactions per company, with company insiders acquiring on average 136,632 shares.

SEC Story Link http://www.sec.gov/Archives/edgar/data/1340652/000120919121007907/xslF345X03/doc4.xml

This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.